Toutes les photos(1)

Key Documents

View All Documentation

Y0000813

Bisoprolol for system suitability

Name: Bisoprolol for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Bisoprolol hemifumarate salt, 1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol hemifumarate salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₁₈H₃₁NO₄ · .5C₄H₄O₄

Numéro CAS:

104344-23-2

Poids moléculaire :

383.48

Numéro MDL:

MFCD00792743

Code UNSPSC :

41116107

ID de substance PubChem :

329831166

Nomenclature NACRES :

NA.24

Produits recommandés

Slide 1 of 10

1 of 10

Y0000812

Bisoprolol fumarate

Y0000877

Bisoprolol for peak identification

BP1228

Bisoprolol Impurity Standard

Y0002187

Rivaroxaban

USP

1075757

Bisoprolol fumarate

Y0001590

Metformin impurity A

Y0000797

Promethazine hydrochloride

USP

1561020

Prilocaine Related Compound B

Sigma-Aldrich

A1260

Amantadine hydrochloride

Millipore

WBLUR

Substrat de peroxydase de raifort Immobilon Crescendo pour western blot, 100 ml

Qualité

pharmaceutical primary standard

Famille d'API

bisoprolol

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES

OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1.CC(C)NCC(O)COc2ccc(COCCOC(C)C)cc2

InChI

1S/2C18H31NO4.C4H4O4/c2*1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4;5-3(6)1-2-4(7)8/h2*5-8,14-15,17,19-20H,9-13H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+

Clé InChI

VMDFASMUILANOL-WXXKFALUSA-N

Informations sur le gène

human ... ADRB1(153)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Étalons de référence analytiques | Sigma-Aldrich

Étalons des instituts de métrologie et des pharmacopées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Bisoprolol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Cardioselective β₁-adrenoceptor antagonist.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

1075804

1075780

1075815

1075799

Pictogrammes

GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H361fd,H373

Conseils de prudence

P202 - P260 - P264 - P280 - P301 + P312 - P308 + P313

Classification des risques

Acute Tox. 4 Oral - Repr. 2 - STOT RE 2

Organes cibles

Heart

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Regulation of cyclic adenosine monophosphate release by selective β2-adrenergic receptor stimulation in human terminal failing myocardium before and after ventricular assist device support.

Astrid Kassner et al.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 31(10), 1127-1135 (2012-09-15)

Response to catecholamines is blunted in terminal heart failure due to β-receptor downregulation and uncoupling from adenylyl cyclase (AC). Improved myocardial responsiveness to catecholamines after ventricular assist device (VAD) support is associated with upregulation of β1-adrenergic receptors (β1-ARs). Little is

Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study.

Akira Sezai et al.

The Journal of thoracic and cardiovascular surgery, 144(5), 1241-1248 (2012-08-04)

We previously performed a trial of intravenous landiolol hydrochloride during and after cardiac surgery (the PASCAL trial) and demonstrated a preventive effect on postoperative atrial fibrillation (AF). In the present study, we investigated the efficacy of increasing the dose and

[Takotsubo cardiomyopathy: a novel beta-adrenergic blocker withdrawal syndrome].

János Tomcsányi et al.

Orvosi hetilap, 154(7), 267-271 (2013-02-12)

The authors describe two cases of takotsubo cardiomyopathy developing after an abrupt withdrawal of carvedilol and bisoprolol. Takotsubo or stress cardiomyopathy is characterized by acute and reversible cardiac dysfunction without coronary artery disease. It is triggered by acute emotional or

Simultaneous acquisition of the dissolution curves of two active ingredients in a binary pharmaceutical association, employing an on-line circulation system and chemometrics-assistance.

Rubén M Maggio et al.

Journal of pharmaceutical and biomedical analysis, 72, 51-58 (2012-11-14)

The association of an on-line circulation system with a chemometrics-assisted UV detection strategy is described as a useful system to continuously monitor the dissolution of a pharmaceutical preparation containing two active ingredients, and as a tool for the simultaneous determination

Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.

Giuseppe Rengo et al.

Circulation. Heart failure, 6(6), 1259-1267 (2013-09-14)

Impaired angiogenesis in the post-myocardial infarction heart contributes to the progression to heart failure. The inhibition of vascular endothelial growth factor (VEGF) signaling has been shown to be crucial for the transition from compensatory hypertrophy to cardiac failure. Importantly, β-adrenergic

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique